Geron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time

MENLO PARK, Calif., April 09, 2017 -- Geron Corporation (Nasdaq:GERN) will host a conference call on April 10, 2017, at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2/3 trial in myelodysplastic syndromes and the Phase 2 trial in myelofibrosis.

Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID number is 6116409. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast will also be available through the company’s website at www.geron.com in the Investors section under Events and at http://edge.media-server.com/m/p/w5mtfw9k. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through May 11, 2017.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected]
[email protected]